158 related articles for article (PubMed ID: 17584139)
1. Pharmacology of CCKRs and SAR studies of peptidic analog ligands.
Noble F
Curr Top Med Chem; 2007; 7(12):1173-9. PubMed ID: 17584139
[TBL] [Abstract][Full Text] [Related]
2. CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology.
Noble F; Roques BP
Prog Neurobiol; 1999 Jul; 58(4):349-79. PubMed ID: 10368033
[TBL] [Abstract][Full Text] [Related]
3. Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors.
Laverman P; Béhé M; Oyen WJ; Willems PH; Corstens FH; Behr TM; Boerman OC
Bioconjug Chem; 2004; 15(3):561-8. PubMed ID: 15149184
[TBL] [Abstract][Full Text] [Related]
4. Phenotypes of mice with invalidation of cholecystokinin (CCK(1) or CCK(2)) receptors.
Noble F; Roques BP
Neuropeptides; 2002; 36(2-3):157-70. PubMed ID: 12359506
[TBL] [Abstract][Full Text] [Related]
5. Structure of cholecystokinin receptor binding sites and mechanism of activation/inactivation by agonists/antagonists.
Fourmy D; Escrieut C; Archer E; Galès C; Gigoux V; Maigret B; Moroder L; Silvente-Poirot S; Martinez J; Fehrentz JA; Pradayrol L
Pharmacol Toxicol; 2002 Dec; 91(6):313-20. PubMed ID: 12688374
[TBL] [Abstract][Full Text] [Related]
6. Strategies for design of non peptide CCK1R agonist/antagonist ligands.
García-López MT; González-Muñiz R; Martín-Martínez M; Herranz R
Curr Top Med Chem; 2007; 7(12):1180-94. PubMed ID: 17584140
[TBL] [Abstract][Full Text] [Related]
7. Involvement of cholecystokinin within craving for cocaine: role of cholecystokinin receptor ligands.
Crespi F; Corsi M; Reggiani A; Ratti E; Gaviraghi G
Expert Opin Investig Drugs; 2000 Oct; 9(10):2249-58. PubMed ID: 11060804
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists).
de Tullio P; Delarge J; Pirotte B
Curr Med Chem; 1999 Jun; 6(6):433-55. PubMed ID: 10213792
[TBL] [Abstract][Full Text] [Related]
9. Cholecystokinin antagonists: pharmacological and therapeutic potential.
Herranz R
Med Res Rev; 2003 Sep; 23(5):559-605. PubMed ID: 12789687
[TBL] [Abstract][Full Text] [Related]
10. Conformationally constrained CCK8 analogues obtained from a rationally designed peptide library as ligands for cholecystokinin type B receptor.
De Luca S; Saviano M; Della Moglie R; Digilio G; Bracco C; Aloj L; Tarallo L; Pedone C; Morelli G
ChemMedChem; 2006 Sep; 1(9):997-1006. PubMed ID: 16915602
[TBL] [Abstract][Full Text] [Related]
11. Peptide/benzodiazepine hybrids as ligands of CCK(A) and CCK(B) receptors.
Escherich A; Lutz J; Escrieut C; Fourmy D; van Neuren AS; Müller G; Schafferhans A; Klebe G; Moroder L
Biopolymers; 2000-2001; 56(2):55-76. PubMed ID: 11592053
[TBL] [Abstract][Full Text] [Related]
12. Use of the chemical structure of peptides as the starting point to design nonpeptide agonists and antagonists at peptide receptors: examples with cholecystokinin and tachykinins.
Horwell DC
Bioorg Med Chem; 1996 Oct; 4(10):1573-6. PubMed ID: 8931926
[TBL] [Abstract][Full Text] [Related]
13. Distinct molecular mechanisms for agonist peptide binding to types A and B cholecystokinin receptors demonstrated using fluorescence spectroscopy.
Harikumar KG; Clain J; Pinon DI; Dong M; Miller LJ
J Biol Chem; 2005 Jan; 280(2):1044-50. PubMed ID: 15520004
[TBL] [Abstract][Full Text] [Related]
14. Quantitative structure-activity relationship studies on cholecystokinin antagonists.
Gupta SP
Curr Pharm Des; 2002; 8(2):111-24. PubMed ID: 11812253
[TBL] [Abstract][Full Text] [Related]
15. The CCK(-like) receptor in the animal kingdom: functions, evolution and structures.
Staljanssens D; Azari EK; Christiaens O; Beaufays J; Lins L; Van Camp J; Smagghe G
Peptides; 2011 Mar; 32(3):607-19. PubMed ID: 21167241
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of either cholecystokinin receptor subtype reduces while antagonists potentiate or sensitize a morphine-induced excitatory response.
Felicio LF; Mazzini BK; Cacheiro RG; Cruz TN; Flório JC; Nasello AG
Peptides; 2001 Aug; 22(8):1299-304. PubMed ID: 11457524
[TBL] [Abstract][Full Text] [Related]
17. Cholecystokinin octapeptide induces endogenous opioid-dependent anxiolytic effects in morphine-withdrawal rats.
Wen D; Sun D; Zang G; Hao L; Liu X; Yu F; Ma C; Cong B
Neuroscience; 2014 Sep; 277():14-25. PubMed ID: 24993476
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationships of bifunctional cyclic disulfide peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.
Agnes RS; Ying J; Kövér KE; Lee YS; Davis P; Ma SW; Badghisi H; Porreca F; Lai J; Hruby VJ
Peptides; 2008 Aug; 29(8):1413-23. PubMed ID: 18502541
[TBL] [Abstract][Full Text] [Related]
19. Cholecystokinin and learning and memory processes.
Hadjiivanova C; Belcheva S; Belcheva I
Acta Physiol Pharmacol Bulg; 2003; 27(2-3):83-8. PubMed ID: 14570153
[TBL] [Abstract][Full Text] [Related]
20. Full and partial agonist activity of C-terminal cholecystokinin peptides at the cloned human CCK-A receptor expressed in Chinese hamster ovary cells.
Dunlop J; Zhang Y; Evans N
Peptides; 1997; 18(6):865-8. PubMed ID: 9285936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
